9th annual Next Generation Pharmaceutical Samples

October 16-17, 2019 | USA

CBI’s 9th annual Next Generation Pharmaceutical Samples returns as the preeminent forum to discuss best practices in physician sample programs. Benefit from compelling content that addresses the biggest emerging issues in sample programs and chart your program growth for 2019 and beyond. This year’s program will look closely at staff training, data priorities, analytics, audits & inspections, state level regulations, emerging technologies, the changing federal landscape and global sample programs.

Spotlight

In the European Union (EU), where strained healthcare systems are facing ever greater demands from an ageing population, generic medicines have played a significant part in controlling costs. Off-patent medicines now account for 92% of the treatment volume in the region. And competition from generic medicines drives the cost of off-patent products down61% from their cost during market exclusivity. This saved payers an estimated €100Bn in 2014 and has contributed to significantly higher access for patients in many countries, across many therapeutic areas. However, over the next several years, the number of small molecule original brands losing their market exclusivity in Europe and the savings opportunities to be had from generic medicines and the competition they create will be dramatically reduced.


OTHER PAST CONFERENCES

Pharmaceutical Science And Drug Manufacturing

December 1-2, 2021 | UAE

Association of Pharmaceutical Research (APR) organizes the "9th World Conference on Pharmaceutical Science and Drug Manufacturing" on 1st & 2nd December 2021, in Dubai. This conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about pharmaceutical science, research methodologies, formulations, manufacturing, and its advances. We invite all the Speakers and Delegates from all over the world to attend this conference.

Advanced Clinical Research and Clinical Trials

November 15-16, 2021 | USA

Clinical Research 2021 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about clinical research and its advances. This is your best opportunity to reach the largest assemblage of participants from Clinical Trials, Clinical Research and Epidemiology community that is from academia, clinical research entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.

Global Conference on Cleaning Validation

November 29-30, 2021 | USA

Cleaning Validation holds a crucial importance concerning the mass manufacturing and different operations in the field of Pharmaceuticals. During the Covid-era people have formed another appreciation for the words like „Clean or Sterile“ and little did we know how hugely they could influence our lives, in the meanwhile pharmaceutical laboratories have always been professionals at keeping the things clean.

Digital Sales and Marketing for Pharma 2021

December 1-2, 2021 | USA

Marketing and Sales are undergoing a period of transformation within pharma – moving from a strategy that was predominately focused on boots on the ground to one which is smaller, leaner and ultimately more digital. With that in mind, Digital Sales and Marketing for Pharma 2021 will be focused on: Developing an effective multi-channel customer engagement strategy across both B2B and B2C channels Leveraging data and analytics to optimize marketing activities and guide marketing investment decisions Utilizing a content marketing approach in order to drive sales ready leads to your sales teams Understanding how best to utilize digital channels in a highly regulated industry Creating and executing plans for marketing and selling specialist therapies

Spotlight

In the European Union (EU), where strained healthcare systems are facing ever greater demands from an ageing population, generic medicines have played a significant part in controlling costs. Off-patent medicines now account for 92% of the treatment volume in the region. And competition from generic medicines drives the cost of off-patent products down61% from their cost during market exclusivity. This saved payers an estimated €100Bn in 2014 and has contributed to significantly higher access for patients in many countries, across many therapeutic areas. However, over the next several years, the number of small molecule original brands losing their market exclusivity in Europe and the savings opportunities to be had from generic medicines and the competition they create will be dramatically reduced.

resources